胰高糖素样肽-1受体激动剂联合钠-葡萄糖共转运蛋白2抑制剂在2型糖尿病中的应用  

Glucagon-Like Peptide-1 Receptor Agonists Combined with Sodium-glucose Transport Protein 2 Inhibitors in Type 2 Diabetes Mellitus

作　　者：王菊兰 李桂平 WANG Julan;LI Guiping(Department of Endocrinology,the First Clinical College of Medicine of Guangdong Medical University(the Third People´s Hospital of Huizhou),Huizhou,Guangdong Province,516000 China)

机构地区：[1]广东医科大学第一临床医学院(惠州市第三人民医院)内分泌科,广东惠州516000

出　　处：《糖尿病新世界》2023年第2期189-193,共5页Diabetes New World Magazine

摘　　要：糖尿病目前是严重威胁人类健康的世界性重大公共卫生问题。因长期血糖控制不佳从而导致各种并发症,严重影响着患者的生活质量。糖尿病的治疗不单单在于血糖的控制,最重要的是并发症的治疗和预防。近年来,对降糖药物的探索中,胰高血糖素样肽-1受体激动剂联合钠葡萄糖协同转运蛋白2抑制剂治疗2型糖尿病且在心血管、肾脏及其他代谢方面有诸多益处。本文综述了胰高血糖素样肽-1受体激动剂联合钠葡萄糖协同转运蛋白2抑制剂在治疗2型糖尿病的应用。Diabetes mellitus is a serious threat to human health worldwide.Long-term poor blood glucose control leads resulting to various complications,and seriously affects the quality of life of patients.The treatment of diabetes is not only the control of blood glucose,the most important is the treatment and prevention of complications.In recent years,in the exploration of hypoglycemic drugs,Glucagon-Like Peptide-1 receptor agonists combined with sodiumglucose transporter protein 2 inhibitors have been shown to have many benefits in cardiovascular,renal and other metabolic aspects in the treatment of type 2 diabetes.This article reviews the application of Glucagon-Like Peptide-1 receptor agonists combined with sodium-glucose transporter protein 2 inhibitors in the treatment of type 2 diabetes mellitus.

关 键 词：胰高血糖素样肽-1受体激动剂 钠葡萄糖协同转运蛋白2抑制剂 2型糖尿病 

分 类 号：R587.2[医药卫生—内分泌]